Michael Bourne, MD
Pulmonary Disease · Salt Lake City, UTNPI 1881030443
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (39.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $5,475 and has fallen 87.2% since, to $703 in 2025.
Across 67 payments — averaging $94.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AstraZeneca$276
- Takeda Pharmaceuticals U.S.A., Inc.$195
- Pulmonx Corporation$137
- Grifols USA, LLC$105
- Insmed, Inc.$77
- plus $459 from 11 others
What the payments were for
- Travel & lodging$2,07333%
- Food & beverage$1,76228%
- Education$2,50039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $5,085 |
| AstraZeneca | 14 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $195 |
| Pulmonx Corporation | 3 | $137 |
| Grifols USA, LLC | 3 | $105 |
| Insmed, Inc. | 3 | $77 |
| Baxter Healthcare | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Merck | 3 | $58 |
| Scpharmaceuticals Inc. | 1 | $55 |
| Viatris Specialty LLC | 2 | $50 |
| Verona Pharma, Inc. | 2 | $46 |
| Procyrion, Inc. | 1 | $33 |
| United Therapeutics Corporation | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,910
How this compares
$6,335 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 40 | $156,144 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $141,287 |
| Breo ElliptaFluticasone/Vilanterol | 107 | $71,571 |
| Dupixent PenDupilumab | 11 | $40,911 |
| Spiriva RespimatTiotropium Bromide | 28 | $36,348 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $28,375 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $25,951 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $19,985 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 68 | $19,421 |
| Arnuity ElliptaFluticasone Furoate | 30 | $18,608 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $18,546 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $14,568 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $12,970 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $12,187 |
| Azelastine Hcl | 247 | $8,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $276 | $38,13858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Kurt FrancisSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.